Forget Cystic Fibrosis: Vertex's Next Growth Engine Could Be Hormone Disorders

In 2012, Vertex Pharmaceuticals (VRTX) achieved a significant milestone by gaining approval for the first drug targeting the root cause of cystic fibrosis (CF), a rare disease impacting lungs and pancreases. Since then, Vertex has grown into the leading player in this sector, delivering robust returns to investors. However, the company is now transitioning into a more diversified stage with a growing range of approved products.

Recent events hint at a potential new growth engine for Vertex in hormone disorders. In September, Vertex concluded the acquisition of Crinetics Pharmaceuticals for roughly $10 billion in cash, marking its most substantial acquisition to date. This deal granted Vertex access to several promising assets. One such asset is Palsonify, an approved medicine addressing acromegaly, a rare hormonal condition wherein the body generates excessive growth hormone, resulting in enlarged bones and organs.

Palsonify is considered a first-line treatment for patients unresponsive to surgery or those whose surgery is unsuccessful. Due to its broad indication and once-daily oral dosing, Palsonify could emerge as a competitive alternative. Vertex projects a market of 20,000 diagnosed acromegaly patients in the U.S., with an additional 35,000 globally, and estimates that only 40% to 50% of patients achieve lasting remission following surgery.

Consequently, there is a substantial opportunity to cater to those who do not benefit from surgical intervention. Apart from Palsonify, Vertex also acquired Atumelnant, a drug under development for congenital adrenal hyperplasia (CAH) and Cushing's syndrome, both rare hormonal disorders. Atumelnant is currently undergoing Phase 3 trials for CAH and Phase 2 trials for Cushing's syndrome.

Vertex estimates that Palsonify and Atumelnant could collectively generate peak revenues surpassing $5 billion. Although this figure represents a fraction of Vertex's $12 billion in annual revenue, the company's core CF franchise has experienced a slowdown in sales growth recently. However, the introduction of Palsonify earlier this year and the anticipated launch of Atumelnant within the next couple of years, contingent on positive clinical trial outcomes, could propel Vertex's hormone disorder portfolio to a substantial growth driver in the medium term.

While Vertex will not solely depend on this new franchise for top-line growth, the company has also gained approvals for products like Casgevy, a gene-editing therapy for two rare blood disorders, and Journavx, a treatment for acute pain. Although these products have not significantly contributed to top-line growth yet, they are expected to do so in the future.

Moreover, Vertex is actively pursuing new launches. Its povetacicept, a medicine for IgA nephropathy, a kidney disease, could receive regulatory approval by the end of November. Additionally, Vertex has several promising pipeline candidates, including inaxaplin, an investigational drug for APOL-1-mediated kidney disease. Despite all these diversification endeavors, Vertex's primary CF franchise is expected to persist in delivering steady revenue, potentially until the company loses patent exclusivity for its key CF drugs in the late 2030s.

In summary, Vertex's business appears stable and promising. The company may achieve significant clinical and regulatory advancements in the coming years, leading to enhanced financial performance and favorable stock market returns. Consequently, Vertex emerges as an attractive healthcare stock for long-term investors.